Infliximab-Axxq

How is Infliximab-Axxq dosed?

Infliximab-Axxq (Intravenous Route) is usually given by a healthcare professional in a medical setting. The dosage and frequency of administration depend on the medical condition being treated, the patient's age, weight, and response to the treatment.

For Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, the typical dose is 5 mg/kg administered intravenously over a period of 2 hours. The dose may be adjusted by your doctor based on your response and any side effects you may experience.

For plaque psoriasis, the typical dose is 250 mg to 500 mg administered intravenously at Weeks 0, 2, 4, 6, 8, and 10, followed by maintenance doses of 250 mg every 8 weeks. Your doctor may adjust the dose based on your response to the treatment.

It is essential to follow your doctor's instructions carefully and not to self-adjust the dose or frequency of administration. If you have any questions or concerns about your dosage, please consult your healthcare provider.

What is the dosage form of Infliximab-Axxq?

The dosage form of Infliximab-Axxq intravenous route is Powder for Solution.

How is Infliximab-Axxq administered?

Infliximab-Axxq (Intravenous Route) is administered through intravenous (IV) infusion.

What are common precautions when taking Infliximab-Axxq?

Common precautions when taking Infliximab-Axxq intravenous route include:

1. Regular progress checks: Your doctor will monitor your or your child's progress through regular visits to ensure the medicine is working properly.

2. Blood and urine tests: These tests may be needed to check for unwanted effects.

3. Infusion reaction precautions: Inform your doctor or nurse immediately if you or your child experience chest pain, fever, chills, itching, hives, rash, dizziness, fainting, lightheadedness, headache, joint pain, difficulty with swallowing, trouble breathing, or swelling of the face, tongue, and throat during or after the infusion.

4. Elderly patients: Elderly patients may be more susceptible to infections, which may require caution when receiving Infliximab-Axxq injection.

5. Breastfeeding: There are no adequate studies to determine the safety of this medication during breastfeeding. Consult your doctor before taking Infliximab-Axxq while breastfeeding.

6. Vaccinations: Avoid having any immunizations (vaccines) without your doctor's approval while being treated with Infliximab-Axxq. Live virus vaccines should not be given with this medicine.

7. Skin reactions: Be cautious of serious skin reactions such as blistering, peeling, or loosening of the skin, chills, cough, diarrhea, fever, itching, joint or muscle pain, red skin lesions, sore throat, sores, ulcers, or white spots in your mouth, or unusual tiredness or weakness. Consult your doctor immediately if any of these occur.

Please consult your doctor for specific guidance and personalized precautions based on your medical history and conditions.